Author of

• 30601

  +

  P2.01 - Advanced NSCLC (ID 159)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 30687

    +

    P2.01-78 - A Meta‑Analysis and Bioinformatics Exploration of the Prognostic Value of TP53 Co-Mutations in EGFR Mutated NSCLC (ID 1241)

    10:15 - 18:15  |  Author(s): Dingzhi Huang
    • Abstract

    Background
    

    As the leading cancer type for the estimated new cancer cases, lung cancer represents the major cause of cancer related worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% to 90% of primary bronchogenic carcinomas and leads the ranking of cancer-related mortality in the western world. TP53 mutations were recently reported as a useful index in predicting the prognosis of lung cancer. However, the prognostic role of TP53 co-mutations in epidermal growth factor receptor (EGFR)mutated NSCLC remains controversial.

    Method
    

    Relevant literatures were retrieved from PubMed, Embase and Web of Science databases. Meta-analysis was performed using hazard ratio (HR) and 95% confidence intervals (CIs) as effect measures. A total of 1146 patients from 7 studies were finally enrolled in the meta-analysis. Information regarding TP53 and EGFR alterations and patients’ survival time in NSCLC was downloaded from the Cancer Genome Atlas Database and The Clinical Lung Cancer Genome Project (CLCGP). Patients were further subdivided into subgroups based on different mutation exons. The distribution of different mutation exon as well as the prognostic value were evaluated. 2660 pieces of data from 2241 NSCLC patient were collected.

    Result
    

    The summary results showed that dual TP53/EGFR mutations predicted poorer overall survival (OS) (HR: 1.38, 95%CI: 1.06–1.81, p < 0.05). Subgroup analysis revealed that dual TP53/EGFR mutations was also associated with poor OS in NSCLC treated by EGFR-TKIs (HR:1.47, 95%CI: 0.88-2.46, P < 0.05). Patients with TP53 mutations in exons 6 and 8 had worse OS compared with patients with TP53 mutations in other exons(HR: 1.22, 95%CI: 0.89–4.33, p < 0.05), especially coexisting with EGFR mutations in exons 20(HR: 1.78, 95%CI:1.13–2.52, p < 0.05).

    Conclusion
    

    In EGFR mutated NSCLC, dual TP53/EGFR mutations suggest poor prognosis, especially in patients treated by EGFR-TKIs. The presence of TP53 mutations in exons 6 and 8 correlated with inferior OS. Larger datasets are required to validate these observations.